MetaCap

C4 Therapeutics (CCCC) vs Kyverna Therapeutics (KYTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

C4 Therapeutics (CCCC) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 1.6% versus a loss of 39.9%. C4 Therapeutics is the larger company by market cap ($325.7 million vs $269.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CCCC+1.64%KYTX-39.92%
+98%+26%-46%
Nov 21, 20251 yearNov 20, 2026
CCCC-59.67%KYTX-85.85%
+87%-7%-102%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CCCC versus KYTX key metrics
MetricCCCCKYTX
Share price$2.48$4.26
Market cap$325.67M$269.33M
1-day change+1.64%-2.52%
YTD return+29.84%-54.68%
1-year return+1.64%-39.92%
5-year return-93.23%—
EPS (TTM)$-0.63$-2.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$35.95M—
Revenue growth (YoY)+1.02%—
Net income (latest FY)$-104.99M$-161.31M
Operating margin-320.53%—
Net margin-292.08%—
52-week high$5.17$13.67
52-week low$1.69$4.18
Distance from 52-week high-52.03%-68.84%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+404.03%+613.62%
Average volume2.57M867.28K
Shares outstanding131.32M63.22M
Employees104172
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CCCC has outperformed KYTX by 41.6 percentage points over the past year.

About C4 Therapeutics

CCCC stock →

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

CCCC vs KYTX FAQ

Which is bigger, C4 Therapeutics or Kyverna Therapeutics?

C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $269.33M for Kyverna Therapeutics (KYTX).

Which stock has performed better over the past year, CCCC or KYTX?

CCCC returned +1.64% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.

Are C4 Therapeutics and Kyverna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons